Apothecary Pharma recalls tirzepatide injections over sterility

GLP-1 injections recalled nationwide over sterility concerns

The FDA classified Apothecary Pharma's nationwide recall of 23 injectable drug vials as Class II. The company previously received a warning over sterile drug production.

Compound GLP-1 injections are being recalled. Here's why

Apothecary Pharma LLC initiated a voluntary recall of GLP-1 injections on Sept. 24 because of a “lack of assurance of sterility." The post Compound GLP-1 injections are being recalled. Here’s why appeared first on Cardinal & Pine.

GLP-1 injections recalled nationwide — what to know about the affected products

The FDA has issued a nationwide recall of compounded GLP-1 tirzepatide injections by Apothecary Pharma to Class II. Check if your weight-loss medication is safe.

Apothecary Pharma recalls tirzepatide injections over sterility

The company received an FDA warning letter in December 2025 citing deficiencies in how it makes sterile drug products